Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Wei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9485-583X; OpenAlex author ID A5100392130. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
90
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: none · 2018: 3 papers · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 17

  1. STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. Co-author DOI 10.1007/s00535-025-02291-3↗
  2. Clostridium butyricum and its metabolite butyrate promote ferroptosis susceptibility in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13402-023-00831-8↗
  3. hENT1's role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients. Co-author DOI 10.1186/s12876-023-02666-x↗
  4. Multimodal data analysis reveals that pancreatobiliary-type ampullary adenocarcinoma resembles pancreatic adenocarcinoma and differs from cholangiocarcinoma. Co-author DOI 10.1186/s12967-022-03473-w↗
  5. CASK regulates Notch pathway and functions as a tumor promoter in pancreatic cancer. Last author DOI 10.1016/j.abb.2021.108789↗
  6. The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancy. Co-author DOI 10.7150/thno.42795↗
  7. Should a standard lymphadenectomy include the No. 9 lymph nodes for body and tail pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.pan.2019.03.005↗
  8. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer. Co-author DOI 10.1186/s40880-019-0367-7↗
  9. Cancer‑associated adipocytes exhibit distinct phenotypes and facilitate tumor progression in pancreatic cancer. Co-author DOI 10.3892/or.2019.7365↗
  10. A novel scoring system predicts postsurgical survival and adjuvant chemotherapeutic benefits in patients with pancreatic adenocarcinoma: Implications for AJCC-… Co-author DOI 10.1016/j.surg.2018.01.017↗
  11. SNX6 predicts poor prognosis and contributes to the metastasis of pancreatic cancer cells via activating epithelial-mesenchymal transition. Last author DOI 10.1093/abbs/gmy110↗
  12. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Co-author DOI 10.1158/0008-5472.can-17-3939↗
  13. Elevated expression of growth-regulated oncogene-alpha in tumor and stromal cells predicts unfavorable prognosis in pancreatic cancer. Co-author DOI 10.1097/md.0000000000004328↗
  14. Increased Risk of Pancreatic Cancer Related to Gallstones and Cholecystectomy: A Systematic Review and Meta-Analysis. Co-author DOI 10.1097/mpa.0000000000000502↗
  15. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  16. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus … Co-author DOI 10.3892/ijo.2015.3128↗
  17. Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. Co-author DOI 10.1089/gtmb.2013.0419↗

Closest collaborators

The 25 strongest of 90 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ran Tao · 1 shared paper, 2025 · strength 0.26
  2. Zongting Gu · 1 shared paper, 2025 · strength 0.26
  3. Xiao Wang · 1 shared paper, 2025 · strength 0.26
  4. Peng Nan · 1 shared paper, 2025 · strength 0.26
  5. Chen Jin · 1 shared paper, 2023 · strength 0.22
  6. Xinyu Huang · 1 shared paper, 2023 · strength 0.22
  7. Hengchao Li · 1 shared paper, 2023 · strength 0.22
  8. Xinzhe Yu · 1 shared paper, 2023 · strength 0.22
  9. Shengping Li · 3 shared papers, 2015–2022 · strength 0.22
  10. Xianjun Yu · 4 shared papers, 2015–2018 · strength 0.21
  11. Xuqing Shen · 1 shared paper, 2023 · strength 0.20
  12. Zhengyan Zhang · 1 shared paper, 2023 · strength 0.20
  13. Junyi Xu · 1 shared paper, 2023 · strength 0.20
  14. Xiaotong Yang · 1 shared paper, 2023 · strength 0.20
  15. Jing Xue · 1 shared paper, 2023 · strength 0.20
  16. Jun Qu · 1 shared paper, 2021 · strength 0.17
  17. Zhiwei Cai · 2 shared papers, 2018–2019 · strength 0.17
  18. Pengfei Hu · 2 shared papers, 2018–2019 · strength 0.17
  19. Chongyi Jiang · 2 shared papers, 2018–2019 · strength 0.17
  20. Quanxing Ni · 3 shared papers, 2015–2018 · strength 0.14
  21. Jian Wang · 3 shared papers, 2015–2018 · strength 0.14
  22. Chenghao Shao · 3 shared papers, 2015–2018 · strength 0.14
  23. Jun Cheng · 1 shared paper, 2022 · strength 0.14
  24. Yize Mao · 1 shared paper, 2022 · strength 0.14
  25. Liqin Li · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.